Yong Yu - Aug 21, 2025 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
SVP, Clinical Development
Signature
/s/ Thomas Zindrick, J.D. Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
Aug 21, 2025
Transactions value $
-$16,032
Form type
4
Date filed
12/11/2025, 08:50 PM
Previous filing
May 13, 2025
Next filing
Aug 29, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yu Yong SVP, Clinical Development C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE /s/ Thomas Zindrick, J.D. Attorney-in-Fact 2025-12-11 0001937482

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Sale -$10.8K -3.22K -2.15% $3.36 147K Aug 21, 2025 Direct F1, F2
transaction GNLX Common Stock Sale -$5.22K -973 -0.66% $5.37 146K Nov 17, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.
F2 The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025.